COF@DNAzyme Empowering Endogenous Copper for One‐Stitch Bioorthogonal Catalysis‐Based Anticancer Therapy
Angewandte Chemie International Edition · 2026
DOI: 10.1002/anie.6633730 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2026. Verfasst von Minhao Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Rare Earth Resource Utilization and Laboratory of Chemical Biology, Changchun Institute of Applied Chemistry, Chinese Academy…. Hauptthemen laut MEDLINE: Copper, DNA, Catalytic, Antineoplastic Agents, Prodrugs. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Natural Science Foundation of Jilin Province.
Abstract (Originalsprache)
Bioorthogonal chemistry, particularly the copper‐catalyzed azide‐alkyne cycloaddition (CuAAC) reaction, holds great promise for in situ prodrug activation to minimize systemic toxicity in disease treatments. However, existing approaches mainly rely on exogenous copper catalysts, which pose a risk of disrupting copper homeostasis and suffer from catalyst deactivation caused by cellular components. Moreover, the staggered administration of catalysts and prodrugs complicates clinical translation and leads to unpredictable reaction time windows. Herein, we construct a “one‐stitch” bioorthogonal catalytic therapy system that harnesses endogenous copper without the need for copper supplements or external reductants. By integrating the DNAzyme CLICK‐17 and the tumor‐targeting aptamer AS1411 onto covalent organic framework (COF) nanoparticles, co‐delivery of both the catalyst and the prodrugs in a single nanoplatform (COF‐P@C‐A) is achieved. Upon internalization by tumor cells, high intracellular glutathione (GSH) and an acidic environment triggered the degradation of COF nanoparticles to simultaneously release CLICK‐17 and the prodrugs while consuming excess GSH, thereby alleviating copper sequestration and enhancing the availability of endogenous Cu(I). CLICK‐17 then efficiently catalyzes the CuAAC reaction for localized drug synthesis, maximizing therapeutic efficacy and minimizing off‐target effects. This strategy offers a safe, synchronized, and clinically translatable approach to bioorthogonal prodrug activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Rare Earth Resource Utilization and Laboratory of Chemical Biology, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, People's Republic of China.
- School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei, Anhui, People's Republic of China.
- Institute of Special Animal and Plant Sciences, Chinese Academy of Agricultural Sciences, Changchun, China.
ORCID-Profile: Fang Pu, Jinsong Ren, Xiaogang Qu
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Natural Science Foundation of Jilin Province
- Changchun Science and Technology Development Plan Project
Zitieren
APA
Jiang, M., Pu, F., Shu, Y., Xu, G., Zhu, J., Peng, Y., Zhang, Y., Song, A., Ren, J., & Qu, X. (2026). COF@DNAzyme Empowering Endogenous Copper for One‐Stitch Bioorthogonal Catalysis‐Based Anticancer Therapy. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.6633730
Vancouver
Jiang M, Pu F, Shu Y, Xu G, Zhu J, Peng Y, et al. COF@DNAzyme Empowering Endogenous Copper for One‐Stitch Bioorthogonal Catalysis‐Based Anticancer Therapy. Angewandte Chemie International Edition. 2026. doi:10.1002/anie.6633730
BibTeX
@article{Jiang2026,
author = {Jiang, Minhao and Pu, Fang and Shu, Yinuo and Xu, Guoshi and Zhu, Jiawei and Peng, Yinghua and Zhang, Yanjie and Song, Anjun and Ren, Jinsong and Qu, Xiaogang},
title = {COF@DNAzyme Empowering Endogenous Copper for One‐Stitch Bioorthogonal Catalysis‐Based Anticancer Therapy},
journal = {Angewandte Chemie International Edition},
year = {2026},
doi = {10.1002/anie.6633730}
}
EUVIMED